세계의 근위축성측색경화증(ALS) 치료 시장 : 부문별 예측(2025-2030년)

The Amyotrophic Lateral Sclerosis Treatment Market was valued at USD 734.42 million in 2023, expected to reach USD 790.52 million in 2024, and is projected to grow at a CAGR of 7.73%, to USD 1,237.05 million by 2030.

Amyotrophic Lateral Sclerosis (ALS) treatment market research encompasses a comprehensive analysis of various therapeutic solutions aimed at managing ALS symptoms, slowing disease progression, and improving patient quality of life. The necessity for ALS treatments is underscored by the severe nature of the disease, which currently lacks a definitive cure, prompting a critical demand for innovative therapies. Treatments typically include the use of neuroprotective drugs, physical therapies, and emerging multidisciplinary approaches that involve genetic and stem cell research. The market is influenced by factors such as advancements in biotechnology, increased funding for neurological research, and an aging population that elevates the prevalence of ALS cases. Key growth opportunities lie in personalized medicine and gene therapy, areas that can be leveraged through strategic partnerships between biotech firms and research institutions. Companies should also consider geographic diversification, tapping into underexplored markets in Asia and South America, where rising healthcare infrastructure and awareness are fostering a keen interest in innovative treatments. However, market growth faces challenges including high R&D costs, stringent regulatory hurdles, and the unpredictable nature of disease progression that complicates treatment efficacy measurement. Intellectual property rights and competition from off-label drugs further constrain the landscape. According to market dynamics, the future of ALS treatment innovation hinges on breakthroughs in CRISPR technologies and biomarker research, which could significantly enhance early detection and therapeutic precision. Stakeholders anticipating growth should heavily invest in scientific collaborations and patient-centric care models to align with the shifting paradigm toward personalized treatment approaches. Understanding market nature indicates that patient advocacy and education will play pivotal roles in reshaping treatment uptake and acceptance. In summary, while navigating regulatory landscapes remains complex, firms that prioritize agility in research and strategic alliances will better position themselves to capture emerging opportunities in the ALS treatment market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Amyotrophic Lateral Sclerosis Treatment Market

The Amyotrophic Lateral Sclerosis Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Significant number of amyotrophic lateral sclerosis patients worldwide
  • Growing awareness about ALS treatment among population
• Market Restraints
  • High cost associated with ALS treatments
• Market Opportunities
  • Increasing research activities to develop novel ALS drugs and treatments
  • Improved healthcare infrastructure across economies
• Market Challenges
  • Stringent approval processes for ALS therapeutics

Porter's Five Forces: A Strategic Tool for Navigating the Amyotrophic Lateral Sclerosis Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Amyotrophic Lateral Sclerosis Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Amyotrophic Lateral Sclerosis Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Amyotrophic Lateral Sclerosis Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Amyotrophic Lateral Sclerosis Treatment Market

A detailed market share analysis in the Amyotrophic Lateral Sclerosis Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Amyotrophic Lateral Sclerosis Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Amyotrophic Lateral Sclerosis Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Amyotrophic Lateral Sclerosis Treatment Market

A strategic analysis of the Amyotrophic Lateral Sclerosis Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Amyotrophic Lateral Sclerosis Treatment Market, highlighting leading vendors and their innovative profiles. These include AB Science SA, Amylyx Pharmaceuticals Inc., Aquestive Therapeutics Inc., Ascend Pharmaceuticals LLC, Biogen Inc., Biohaven Pharmaceutical Holding Co Ltd, BrainStorm Cell Limited, Corestem, Inc., Cytokinetics, Incorporated, F. Hoffmann-La Roche AG, Genervon Biopharmaceuticals, LLC, Hackensack Meridian Health, Inc., Implicit Bioscience Ltd., Ionis Pharmaceuticals, Inc., ITF Pharma, Inc., Kringle Pharma, Inc., Mitsubishi Tanabe Pharma Corporation, Orion Corporation, Orphazyme A/S, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sanofi-Aventis Groupe S.A., Sun Pharmaceutical Industries Ltd, and Treeway B.V..

Market Segmentation & Coverage

This research report categorizes the Amyotrophic Lateral Sclerosis Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Treatment, market is studied across Medication and Stem Cell Therapy. The Medication is further studied across Edaravone and Riluzole.
• Based on Distribution Channel, market is studied across Hospital Pharmacies and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Significant number of amyotrophic lateral sclerosis patients worldwide
    • 5.1.1.2. Growing awareness about ALS treatment among population
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with ALS treatments
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing research activities to develop novel ALS drugs and treatments
    • 5.1.3.2. Improved healthcare infrastructure across economies
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent approval processes for ALS therapeutics
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Amyotrophic Lateral Sclerosis Treatment Market, by Treatment

• 6.1. Introduction
• 6.2. Medication
  • 6.2.1. Edaravone
  • 6.2.2. Riluzole
• 6.3. Stem Cell Therapy

7. Amyotrophic Lateral Sclerosis Treatment Market, by Distribution Channel

• 7.1. Introduction
• 7.2. Hospital Pharmacies
• 7.3. Retail Pharmacies

8. Americas Amyotrophic Lateral Sclerosis Treatment Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Amyotrophic Lateral Sclerosis Treatment Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Amyotrophic Lateral Sclerosis Treatment Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AB Science SA
• 2. Amylyx Pharmaceuticals Inc.
• 3. Aquestive Therapeutics Inc.
• 4. Ascend Pharmaceuticals LLC
• 5. Biogen Inc.
• 6. Biohaven Pharmaceutical Holding Co Ltd
• 7. BrainStorm Cell Limited
• 8. Corestem, Inc.
• 9. Cytokinetics, Incorporated
• 10. F. Hoffmann-La Roche AG
• 11. Genervon Biopharmaceuticals, LLC
• 12. Hackensack Meridian Health, Inc.
• 13. Implicit Bioscience Ltd.
• 14. Ionis Pharmaceuticals, Inc.
• 15. ITF Pharma, Inc.
• 16. Kringle Pharma, Inc.
• 17. Mitsubishi Tanabe Pharma Corporation
• 18. Orion Corporation
• 19. Orphazyme A/S
• 20. Otsuka Pharmaceutical Co., Ltd.
• 21. Pfizer Inc.
• 22. Sanofi-Aventis Groupe S.A.
• 23. Sun Pharmaceutical Industries Ltd
• 24. Treeway B.V.